Lytix Biopharma (LYTIX) Study Update summary

Study design and objectives

• Phase 2 study of LTX-315 in basal cell carcinoma (BCC), the most common skin cancer globally, included 93 patients and focused on efficacy and safety.

• The study aims to position LTX-315 as a potential first-line therapy for BCC.

Key results and clinical impact

• LTX-315 achieved an average 86% reduction in tumor size and complete elimination in over 50% of patients, with a 51% complete clearance rate reported.

• Patients with residual carcinomas saw a 70–71% average reduction in tumor size, with no serious or severe adverse events reported.

• LTX-315 may offer a less invasive alternative to surgery, reducing the need for large excisions and minimizing scarring.

• Immunological analyses are ongoing to assess LTX-315's ability to activate the immune system and prevent new tumors.

• LTX-315's dual mechanism—direct tumor cell killing and immune activation—could provide lasting protection against recurrence.

Market potential and commercial outlook

• BCC is the most common cancer globally, with a projected market size of $11.5 billion by 2028 and annual growth over 7%, with 3.6 million new US cases annually.

• Lytix stands to receive up to $110 million in milestone payments and 10–15% tiered royalties from Verica/Verrica for LTX-315.

• Dermatologists and surgeons view LTX-315 as a potential first-line or neoadjuvant therapy, especially for patients unsuitable for surgery.

• LTX-315 could represent a paradigm shift in BCC treatment, particularly for tumors in cosmetically sensitive areas.

• Verrica has experience commercializing dermatology drugs, supporting LTX-315's path to market.